Aurinia Historical Income Statement
| AUPH Stock | USD 8.85 0.14 1.61% |
Historical analysis of Aurinia Pharmaceuticals income statement accounts such as Interest Expense of 2.9 M, Selling General Administrative of 204.8 M or Total Revenue of 184.3 M can show how well Aurinia Pharmaceuticals performed in making a profits. Evaluating Aurinia Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Aurinia Pharmaceuticals's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Aurinia Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Aurinia Pharmaceuticals is a good buy for the upcoming year.
Aurinia |
About Aurinia Income Statement Analysis
Aurinia Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Aurinia Pharmaceuticals shareholders. The income statement also shows Aurinia investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Aurinia Pharmaceuticals Income Statement Chart
Add Fundamental
Total Revenue
Total revenue comprises all receipts Aurinia Pharmaceuticals generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Aurinia Pharmaceuticals. It is also known as Aurinia Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Income Before Tax
Income Before Tax which can also be referred as pre-tax income is reported on Aurinia Pharmaceuticals income statement and is an important metric when analyzing Aurinia Pharmaceuticals profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.Most accounts from Aurinia Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Aurinia Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aurinia Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Aurinia Stock please use our How to Invest in Aurinia Pharmaceuticals guide.As of now, Aurinia Pharmaceuticals' Total Revenue is increasing as compared to previous years. The Aurinia Pharmaceuticals' current Gross Profit is estimated to increase to about 169.4 M, while Operating Income is forecasted to increase to (87.1 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 225.2M | 239.8M | 253.1M | 265.7M | Cost Of Revenue | 1.1M | 5.7M | 14.1M | 7.6M |
Aurinia Pharmaceuticals income statement Correlations
Click cells to compare fundamentals
Aurinia Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Aurinia Pharmaceuticals income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 1.5M | 1.4M | 2.8M | 2.7M | 11.6M | 12.2M | |
| Interest Expense | 39K | 5.3M | 529K | 5.1M | 2.8M | 2.9M | |
| Selling General Administrative | 22.2M | 96.0M | 171.4M | 196.4M | 195.0M | 204.8M | |
| Total Revenue | 318K | 50.1M | 45.6M | 134.0M | 175.5M | 184.3M | |
| Gross Profit | (52.5M) | (209K) | 44.5M | 128.4M | 161.4M | 169.4M | |
| Other Operating Expenses | 76.6M | 147.6M | 226.3M | 245.5M | 267.2M | 280.6M | |
| Operating Income | (82.5M) | (104.3M) | (180.7M) | (111.5M) | (91.7M) | (87.1M) | |
| Ebit | (82.5M) | (104.3M) | (180.2M) | (111.5M) | (74.7M) | (71.0M) | |
| Research Development | 52.9M | 50.3M | 51.1M | 45.0M | 49.6M | 52.1M | |
| Ebitda | (81.0M) | (102.9M) | (177.4M) | (108.8M) | (63.0M) | (59.9M) | |
| Cost Of Revenue | 52.9M | 50.3M | 1.1M | 5.7M | 14.1M | 7.6M | |
| Total Operating Expenses | 76.6M | 147.6M | 225.2M | 239.8M | 253.1M | 265.7M | |
| Income Before Tax | (123.7M) | (102.8M) | (180.2M) | (106.4M) | (77.5M) | (73.6M) | |
| Total Other Income Expense Net | (41.2M) | 1.5M | 529K | 5.1M | 14.2M | 14.9M | |
| Net Income | (123.8M) | (102.7M) | (181.0M) | (108.2M) | (78.0M) | (74.1M) | |
| Income Tax Expense | 144K | (94K) | 760K | 1.8M | 551K | 1.1M | |
| Net Income From Continuing Ops | (123.8M) | (102.7M) | (181.0M) | (108.2M) | (77.2M) | (73.3M) | |
| Net Income Applicable To Common Shares | (88.4M) | (102.7M) | (181.0M) | (108.2M) | (97.4M) | (92.5M) | |
| Interest Income | 2.7M | 1.5M | 529K | 5.1M | 15.3M | 16.1M | |
| Net Interest Income | 2.7M | 1.5M | 529K | 5.1M | 13.9M | 14.6M | |
| Reconciled Depreciation | 1.5M | 1.4M | 2.8M | 2.7M | 6.9M | 7.3M | |
| Tax Provision | 144K | (94K) | 760K | 1.8M | 947K | 670.6K |
Currently Active Assets on Macroaxis
When determining whether Aurinia Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aurinia Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aurinia Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aurinia Pharmaceuticals Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aurinia Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Aurinia Stock please use our How to Invest in Aurinia Pharmaceuticals guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aurinia Pharmaceuticals. If investors know Aurinia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aurinia Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.15) | Revenue Per Share 1.536 | Quarterly Revenue Growth 0.243 | Return On Assets (0.02) | Return On Equity (0.06) |
The market value of Aurinia Pharmaceuticals is measured differently than its book value, which is the value of Aurinia that is recorded on the company's balance sheet. Investors also form their own opinion of Aurinia Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Aurinia Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aurinia Pharmaceuticals' market value can be influenced by many factors that don't directly affect Aurinia Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aurinia Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aurinia Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aurinia Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.